BioCryst Pharma (BCRX) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.72 -3.51%
EPS Growth %: +6.7%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
CCEL, SLP, TMQ, More
EPS Growth %: +6.7%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.32), $0.02 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $63.33 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Key things to know ahead of SK Hynix’s blockbuster US listing
- ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half
- Northern Technologies (NTIC) Misses Q3 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
